Novel, proprietary treatement for Sickle Cell Disease currently in clinical phase II.

Learn more

Sickle Cell Disease

An orphan disease with large unmet medical need.

Learn more

Modus Therapeutics to Present at Biotech Showcase 2018 in San Francisco

Modus Therapeutics announces paper in PLOS ONE demonstrating the anti-adhesive properties of sevuparin in malaria patients

Learn more about our ongoing Phase 2 Study
SCD Therapeutics Conference, 2016

Modus colleagues presented our story at the 5th Annual Sickle Cell Disease Therapeutics conference in New York in October

Poster presented at ASH 2016
La Biotech Interview with Modus

Learn more about our study in the Middle East